Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota
1
Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), and Red Española de Investigación en Patología Infecciosa (REIPI), 28034 Madrid, Spain
2
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), and Red Española de Investigación en Patología Infecciosa (REIPI), 28034 Madrid, Spain
3
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain
*
Author to whom correspondence should be addressed.
Genes 2021, 12(1), 41; https://doi.org/10.3390/genes12010041
Received: 27 November 2020 / Revised: 20 December 2020 / Accepted: 29 December 2020 / Published: 30 December 2020
(This article belongs to the Special Issue Genetics of Antimicrobial Resistance)
The aim was to describe the safety of indefinite administration of antibiotics, the so-called suppressive antibiotic therapy (SAT) and to provide insight into their impact on gut microbiota. 17 patients with SAT were recruited, providing a fecal sample. Bacterial composition was determined by 16S rDNA massive sequencing, and their viability was explored by PCR-DGGE with and without propidium monoazide. Presence of antibiotic multirresistant bacteria was explored through the culture of feces in selective media. High intra-individual variability in the genera distribution regardless of the antibiotic or antibiotic administration ingestion period, with few statistically significant differences detected by Bray-Curtis distance-based principle component analysis, permutational multivariate analysis of variance and linear discriminant analysis effect size analysis. However, the microbiota composition of patients treated with both beta-lactams and sulfonamides clustered by a heat map. Curiously, the detection of antibiotic resistant bacteria was almost anecdotic and CTX-M-15-producing E. coli were detected in two subjects. Our work demonstrates the overall clinical safety of SAT and the low rate of the selection of multidrug-resistant bacteria triggered by this therapy. We also describe the composition of intestinal microbiota under the indefinite use of antibiotics for the first time.
View Full-Text
Keywords:
suppressive antibiotic therapy; gut microbiota; PCR-DGGE; bacterial viability; propidium monoazide; antibiotic multirresistant colonization
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Escudero-Sánchez, R.; Ponce-Alonso, M.; Barragán-Prada, H.; Morosini, M.I.; Cantón, R.; Cobo, J.; del Campo, R. Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota. Genes 2021, 12, 41.
AMA Style
Escudero-Sánchez R, Ponce-Alonso M, Barragán-Prada H, Morosini MI, Cantón R, Cobo J, del Campo R. Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota. Genes. 2021; 12(1):41.
Chicago/Turabian StyleEscudero-Sánchez, Rosa; Ponce-Alonso, Manuel; Barragán-Prada, Hugo; Morosini, María I.; Cantón, Rafael; Cobo, Javier; del Campo, Rosa. 2021. "Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota" Genes 12, no. 1: 41.
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit